Sandoz: Bringing Opportunities to Customers and Patients
Sandoz is a leading global player in the generic pharmaceutical industry with a significant portfolio of approximately 1000 high-quality, affordable products that are no longer protected by patents. The employees of Sandoz are committed to delivering a full range of traditional generic medicines, as well as going a step further by constantly seeking new ways to improve patients’ quality of life.
Sandoz’ decades of experience, combined with its global development and production network, enable the company to develop and manufacture the difficult-to-make generics that many other companies cannot or do not make. Sandoz produces far more than just traditional off-patent products. The company differentiates itself from other companies by developing and producing difficult-to-make generics that require an exceptionally high degree of expertise and knowledge and often involve complex high-tech delivery systems. These range from oral solids and inhalers through patch technologies to state-of-the-art biosimilars—followon versions of biopharmaceuticals following patent expiry.
The global Research & Development centers of Sandoz work to ensure that the company continually brings opportunities to customers and patients. The 8 major global development centers and a worldwide network of production sites and technology centers of excellence pursue not only tablets and capsules but injectables, creams, ointments, and other dosage forms. These generic products include antibiotics, central nervous system disorder treatments, gastrointestinal medicines, cardiovascular treatments, and hormone therapies.
The introduction of the Omnitrope Pen 5 with liquid cartridge for injection and the Omnitrope Pen 10 with liquid cartridge for injection—new forms of the first follow-on version of a recombinant biotechnology drug—have further positioned Sandoz as a leader in the emerging field of follow-on biologics.
The Sandoz pipeline is robust and, as the second largest generic supplier in the United States, the company is uniquely positioned to continue to expand its product portfolio offerings. Sandoz continues to differentiate itself through its ability to develop and produce difficult-to-make medicines. The company is well on its way to achieving its mission to be the main provider of high-quality, affordable medicines, helping to secure long-term access to health care for people around the world.
For more information, visit www.us.sandoz.com
Christine Mundkur President & Chief Executive Officer, Sandoz Inc. Head, Commercial Operations, North America
Mycophenolate Mofetil Capsules, 250 and 500 mg
Amlodipine Besylate and Benazepril HCl, 5 mg/10 mg, 5 mg/20 mg, and 10 mg/20 mg